These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10434314)

  • 21. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer and PSA screening.
    Mameghan H
    Aust Fam Physician; 1999 Aug; 28(8):777-81. PubMed ID: 10495525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program.
    Hamashima C; Sobue T; Muramatsu Y; Saito H; Moriyama N; Kakizoe T
    Jpn J Clin Oncol; 2006 May; 36(5):301-8. PubMed ID: 16735372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K; Babaian RJ
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
    Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of prostate cancer screening in Thai elderly.
    Tantiwong A; Soontrapa S; Sujijantrarat P; Vanprapar N; Sawangsak L
    J Med Assoc Thai; 2002 Apr; 85(4):502-8. PubMed ID: 12118499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer screening in the primary care setting: the role of the primary care physician in screening for breast, cervical, colorectal, lung, ovarian, and prostate cancers.
    Miser WF
    Prim Care; 2007 Mar; 34(1):137-67. PubMed ID: 17481991
    [No Abstract]   [Full Text] [Related]  

  • 28. Controversies regarding screening for prostate cancer.
    Crawford ED; Thompson IM
    BJU Int; 2007 Jul; 100 Suppl 2():5-7. PubMed ID: 17594348
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
    Hernández J; Thompson IM
    Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PSA related screening of prostate cancer. Panic or improvement?].
    Fornara P; Jurczok A
    Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benign prostatic hyperplasia, prostate cancer and other prostate diseases diagnosed as a result of screening procedure among 1,004 men in the Lublin district.
    Opalińska E; Stoma F; Michalak A; Latalski M; Goniewicz M
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):493-501. PubMed ID: 12898966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices.
    Noe M; Schroy P; Demierre MF; Babayan R; Geller AC
    Cancer Causes Control; 2008 Feb; 19(1):1-12. PubMed ID: 17906935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer screening: clinical applications and challenges.
    Brawley OW
    Urol Oncol; 2004; 22(4):353-7. PubMed ID: 15283896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
    van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
    J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on screening for prostate cancer with prostate-specific antigen.
    Schmid HP; Riesen W; Prikler L
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):71-8. PubMed ID: 15094160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
    J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.